Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 445

Similar articles for PubMed (Select 18813809)

1.

Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.

Bierer S, Herrmann E, Köpke T, Neumann J, Eltze E, Hertle L, Wülfing C.

Oncol Rep. 2008 Oct;20(4):721-5.

PMID:
18813809
2.

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.

Shibasaki N, Yamasaki T, Kanno T, Arakaki R, Sakamoto H, Utsunomiya N, Inoue T, Tsuruyama T, Nakamura E, Ogawa O, Kamba T.

PLoS One. 2015 Jun 26;10(6):e0130980. doi: 10.1371/journal.pone.0130980. eCollection 2015.

3.

VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma.

Lkhagvadorj S, Oh SS, Lee MR, Jung JH, Chung HC, Cha SK, Eom M.

J Lifestyle Med. 2014 Mar;4(1):64-70. doi: 10.15280/jlm.2014.4.1.64. Epub 2014 Mar 31.

4.

Papillary renal cell carcinoma: A review of the current therapeutic landscape.

Courthod G, Tucci M, Di Maio M, Scagliotti GV.

Crit Rev Oncol Hematol. 2015 May 27. pii: S1040-8428(15)00097-9. doi: 10.1016/j.critrevonc.2015.05.008. [Epub ahead of print] Review.

PMID:
26052049
5.

Angiomyolipoma with Minimal Fat: Differentiation From Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma by Texture Analysis on CT Images.

Yan L, Liu Z, Wang G, Huang Y, Liu Y, Yu Y, Liang C.

Acad Radiol. 2015 May 29. pii: S1076-6332(15)00188-9. doi: 10.1016/j.acra.2015.04.004. [Epub ahead of print]

PMID:
26031228
6.

Clear Cell Papillary Renal Cell Carcinoma and Renal Angiomyoadenomatous Tumor: Two Variants of a Morphologic, Immunohistochemical, and Genetic Distinct Entity of Renal Cell Carcinoma.

Deml KF, Schildhaus HU, Compérat E, von Teichman A, Storz M, Schraml P, Bonventre JV, Fend F, Fleige B, Nerlich A, Gabbert HE, GaBler N, Grobholz R, Hailemariam S, Hinze R, Knüchel R, Lhermitte B, Nesi G, Rüdiger T, Sauter G, Moch H.

Am J Surg Pathol. 2015 Jul;39(7):889-901. doi: 10.1097/PAS.0000000000000456.

PMID:
25970683
7.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, Linsenmayer D, Hattersley M, Smith A, Wilson J, Cairo S, Déas O, Nicolle D, Adam A, Zinda M, Reimer C, Fawell SE, Clark EA, D'Cruz CM.

Clin Cancer Res. 2015 Jun 15;21(12):2811-9. doi: 10.1158/1078-0432.CCR-14-2685. Epub 2015 Mar 16.

PMID:
25779944
8.

Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma.

Wan L, Huang J, Chen J, Wang R, Dong C, Lu S, Wu X.

J BUON. 2015 Jan-Feb;20(1):188-95.

PMID:
25778315
9.

Kidney cancer: Orchestration of immune checkpoints has prognostic value in ccRCC.

Stone L.

Nat Rev Urol. 2015 Apr;12(4):182. doi: 10.1038/nrurol.2015.40. Epub 2015 Mar 3. No abstract available.

PMID:
25732858
10.

Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.

Chen F, Huhdanpaa H, Desai B, Hwang D, Cen S, Sherrod A, Bernhard JC, Desai M, Gill I, Duddalwar V.

Springerplus. 2015 Feb 10;4:66. doi: 10.1186/s40064-015-0823-z. eCollection 2015.

11.

Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.

Kocarslan S, Guldur ME, Ekinci T, Ciftci H, Ozardali HI.

J Cancer Res Ther. 2014 Oct-Dec;10(4):1076-81. doi: 10.4103/0973-1482.137988.

12.

Pathology, therapy and prognosis of papillary renal carcinoma.

Fernandes DS, Lopes JM.

Future Oncol. 2015 Jan;11(1):121-32. doi: 10.2217/fon.14.133.

PMID:
25572787
13.

Spontaneous rupture of the kidney affected by multifocal papillary renal cell carcinoma.

Dell'Atti L.

Rare Tumors. 2014 Dec 16;6(4):5568. doi: 10.4081/rt.2014.5568. eCollection 2014 Oct 27.

14.

Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.

Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK.

PLoS One. 2014 Dec 26;9(12):e116101. doi: 10.1371/journal.pone.0116101. eCollection 2014.

15.

[Value of VEGF-C, VEGF-D and VEGFR-3 levels combined with serum TSH in diagnosis of papillary thyroid carcinoma].

Huang J, Li Y, Xue G, Zhang W, Li S, Zhang J, Wu J.

Nan Fang Yi Ke Da Xue Xue Bao. 2014 Dec;34(12):1814-7, 1821. Chinese.

PMID:
25537909
16.

Expression of vascular endothelial growth factor-C (VEGF-C) and its receptor (VEGFR-3) in the glial reaction elicited by human mesenchymal stem cell engraftment in the normal rat brain.

Shin YJ, Riew TR, Park JH, Pak HJ, Lee MY.

J Histochem Cytochem. 2015 Mar;63(3):170-80. doi: 10.1369/0022155414564218. Epub 2014 Dec 3.

PMID:
25473093
17.

Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, Cheville JC, Wu KJ, Frenkel E, Rakheja D, Stefanius K, Brugarolas J, Parker AS.

Urol Oncol. 2015 Jan;33(1):23.e9-14. doi: 10.1016/j.urolonc.2014.10.014. Epub 2014 Nov 24.

PMID:
25465300
18.

Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.

van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM.

Drug Resist Updat. 2014 Oct-Dec;17(4-6):77-88. doi: 10.1016/j.drup.2014.10.003. Epub 2014 Oct 7.

PMID:
25457974
19.

Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma.

Mangolini A, Bonon A, Volinia S, Lanza G, Gambari R, Pinton P, Russo GR, Del Senno L, Dell'Atti L, Aguiari G.

FEBS Open Bio. 2014 Nov 4;4:952-65. doi: 10.1016/j.fob.2014.10.016. eCollection 2014.

20.

Delta-like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinoma.

Wang W, Yu Y, Wang Y, Li X, Bao J, Wu G, Chang H, Shi T, Yue Z.

Oncol Lett. 2014 Dec;8(6):2627-2633. Epub 2014 Sep 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk